Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing to Power the Next Era of DNA-Enabled Industries
Ansa’s enzyme-based approach will dramatically accelerate innovation across almost every industry enabled by synthetic DNA-- from biologic therapeutics such as antibodies, gene therapies, and cell therapies, to the biomanufacturing of chemicals, materials, foods, and biofuels, and even to futuristic applications such as DNA-based data storage. The technology also has the potential to unlock new areas of life sciences research that have yet to be explored.
- The company has raised a total of $82 million from private financings to date.
- To support this development, Ansa will expand its state-of-the-art R&D and manufacturing facilities and will grow its multidisciplinary team across biochemistry, chemistry, engineering, bioinformatics, and operations.
- Ansa is on a mission to streamline the writing of DNA to power the next era of DNA-enabled industries.
- Ansa Biotechnologies is building a fast and reliable DNA synthesis service to accelerate synthetic biology research.